Trial Profile
A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via One or Two Suprachoroidal Space (SCS) Injections in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs RGX 314 (Primary) ; Ranibizumab; Steroids
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms AAVIATE
- Sponsors AbbVie
- 27 Feb 2024 According to a REGENXBIO media release, company expects to share new program and data updates for this Phase II AAVIATE trial in mid-2024.
- 16 Jan 2024 According to a REGENXBIO media release, the company will host a conference call on Tuesday, January 16 to discuss new data from this study.
- 16 Jan 2024 According to a REGENXBIO media release, the company presented new data presented at the Hawaiian Eye and Retina meeting in Maui, HI.